LILRB3/CD85a/ILT5, His & Avi, Human
LILRB3/CD85a/ILT5, His & Avi, Human

Immobilized LILRB3/CD85a/ILT5, His & Avi, Human, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB3 Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA.

LILRB3/CD85a/ILT5, His & Avi, Human

The purity of LILRB3/CD85a/ILT5, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

LILRB3/CD85a/ILT5, His & Avi, Human

LILRB3/CD85a/ILT5, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LILRB3/CD85a/ILT5, His & Avi, Human

Leukocyte immunoglobulin-like receptor subfamily B (LILRB3), also known as ILT5, LIR3, and CD85a, is an immunoglobulin superfamily member that is involved in immune regulation. Subfamily B members have cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1.LILRB3 may act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor.
Z05599
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRB3/CD85a/ILT5 (Gly24-Glu443)_x000D_
Accession # O75022-1		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-72 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LILRB3/CD85a/ILT5, His & Avi, Human
    • LILRB3/CD85a/ILT5, His & Avi, Human

    Immobilized LILRB3/CD85a/ILT5, His & Avi, Human, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-LILRB3 Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA.

  • LILRB3/CD85a/ILT5, His & Avi, Human
    • LILRB3/CD85a/ILT5, His & Avi, Human

    The purity of LILRB3/CD85a/ILT5, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • LILRB3/CD85a/ILT5, His & Avi, Human
    • LILRB3/CD85a/ILT5, His & Avi, Human

    LILRB3/CD85a/ILT5, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Leukocyte immunoglobulin-like receptor subfamily B (LILRB3), also known as ILT5, LIR3, and CD85a, is an immunoglobulin superfamily member that is involved in immune regulation. Subfamily B members have cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1.LILRB3 may act as receptor for class I MHC antigens. Becomes activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor.
Synonyms CD85a; ILT5; ILT-5; LILRB3; LIR3; LIR3CD85A; LIR-3MGC138403; PIRB; HL9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.